BioNTech: More Than a One Hit Wonder?

DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.

$BNTX – Q3 FY12/2025 Earnings Review

by Nathan Brinkman

BioNTech is a biotechnology company developing mRNA-based therapeutics, immunotherapies, and vaccines across infectious disease and oncology. Like Moderna, BioNTech generated historic revenues during the COVID-19 pandemic through its partnered Pfizer-BioNTech vaccine (Comirnaty). Post-pandemic, BioNTech faces a similar existential question: Can it convert pandemic windfalls into a sustainable, multi-product powerhouse?

BioNTech’s strategic emphasis is more oncology-centric than Moderna’s, with a therapeutic area pipeline focused only on Oncology and Infectious Diseases. Within these therapeutics areas, BioNTech has 3 therapeutic platforms: mRNA based, Protein based, and Cell Therapy based.

mRNA based platforms include the following technologies:

• FIXVac - indication specific mRNA cancer vaccines.
• iNeST - individualized mRNA cancer vaccines designed to target mutations specific to an individual's cancer type.
• Infectious Disease Vaccines - vaccines against infectious disease targets.
• RiboCytokines - nucleoside-modified mRNA encoded for cytokines overcoming issues with current cytokine therapies.

Protein based platforms include the following technologies:

• Next generation checkpoint immunomodulators - multi-specific antibodies designed to activate immune cells via multiple routes.
• Antibody-drug conjugates - tumor - specific antibodies combined with an anticancer chemotherapy for precise and effective destruction of a cancer cell.
• Next generation synthetic lysins - alternatives to antibiotic resistant bacteria.
• Targeted cancer antibody discovery

Cell Therapy based platforms currently only include the CAR-T cell platform combining a CAR-T cell amplifying RNA vaccine (CARVac) with CAR-T cell therapy boosting cell activity versus traditional methods.

Since the peak of the pandemic, BioNTech’s stock—like Moderna’s—has been severely beaten down, currently trading around ~75–80% off its all-time high.

With COVID revenues declining and the oncology pipeline still in clinical development, investors are asking: Is BioNTech a one-hit wonder, or is Act II finally on the horizon?

Inner Circle members - read on!